This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
PEACE-3 Trial
PROfound Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
CORE-001 Study
ADSTILADRIN
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
ASTRO 2024
IBCN 2024
ESMO 2024
BCAN TT 2024
ASCO 2024
All Conferences
View All
PCF
UroToday Home
Conference Highlights
ASCO 2023
ASCO 2023 Prostate Cancer
ASCO 2023
Prostate Cancer
Testicular and Penile Cancer
Press Releases
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Carcinoma
ASCO 2023 Prostate Cancer
Viewing 841-860 of 11745 articles
ASCO GU 2024: The NEPI Trial: A Randomized Phase I/II Study of Neoadjuvant Treatment with 177-Lutetium-PSMA-617 with or without Ipilimumab in Patients with Very High-Risk Prostate Cancer Who Are Candidates for Radical Prostatectomy
ASCO GU 2024: A Randomized, Non-Comparative, Phase II Multicenter Trial of Short-Term Darolutamide Concomitant to Radiation Therapy for Patients with Unfavorable Intermediate-Risk Prostate Cancer: DARIUS (AFU-GETUG P15)
ASCO GU 2024: Assessing the Clinical Utility of Rapid Post-Therapy Whole-Body Digital SPECT/CT in Evaluating Early Treatment Response of 177Lu-PSMA-617 Treatment
ASCO GU 2024: Infigratinib vs Placebo in Patients with Resected Urothelial Cancer Bearing FGFR3 Mutation or Fusion: Primary DFS Analysis from the Phase 3, Randomized PROOF302 Study
ASCO GU 2024: Association Between SPECT/CT Total Tumor Volume and New Lesions in Early Cycles of 177Lu-PSMA-617 and PFS and OS in Men with mCRPC
ASCO GU 2024: Neoadjuvant Combined Chemotherapy and Immunotherapy for Upper Tract Urothelial Carcinoma: Preliminary Results From a Phase II Study
ASCO GU 2024: Association Between PET-Based TheraP Eligibility and 177Lu-PSMA-617 Outcomes in VISION-Eligible Patients with mCRPC
ASCO GU 2024: Application of Artificial Intelligence Features of Nuclear Morphology from BLASST-1 (Bladder Cancer Signal Seeking Trial) of Nivolumab, Gemcitabine, and Cisplatin in Patients with MIBC Undergoing Cystectomy
ASCO GU 2024: Implementation Outcomes of a Multidisciplinary Approach for Lu177-PSMA-617 Therapy
ASCO GU 2024: Baseline Characteristics of Patients with PSMA-PET–positive and –Negative Disease with High-Risk of BCR After RP in the Ongoing Phase 3 PRIMORDIUM Study
ASCO GU 2024: Evaluating Clinical Outcomes with Systemic Therapy Given After Progression on PSMA Radioligand Therapy in Patients with mCRPC
ASCO GU 2024: Setting the Stage: Biochemical Recurrence After Local Treatment for Prostate Cancer
ASCO GU 2024: Low and High Volume Disease in mHSPC, from CHAARTED to PSMA-PET: An International Multicenter Retrospective Study
ASCO GU 2024: Neoadjuvant Nivolumab + Ipilimumab in Cisplatin-Ineligible Patients with Upper Tract Urothelial Cancer: Updated Results
ASCO GU 2024: RC48-ADC Versus BCG in Adjuvant Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer with HER2 Over-Expression: A Real-World Retrospective Study
ASCO GU 2024: Patient Reported Outcomes Among Patients with mCRPC by HRR Mutations Gene Clusters: Findings from the Phase 3 TALAPRO-2 Study Cohort 2
ASCO GU 2024: Patient Outcomes After Therapy with 177Lu-PSMA-617 for mCRPC: A Tertiary Center Experience
ASCO GU 2024: Patient-Reported Outcomes in Patients with BRCA1/2-Altered mCRPC Receiving Niraparib with Abiraterone Acetate and Prednisone: Results from MAGNITUDE Study
ASCO GU 2024: Patient-Reported Outcomes with Talazoparib + Enzalutamide vs. Placebo + Enzalutamide in Men with mCRPC: Subgroup Analysis of Patients with Novel Hormonal Therapy Pretreatment in the TALAPRO-2 Study
ASCO GU 2024: Prognostic Value of AI–Driven Tumor Estimation of PSMA PET Total Tumor Burden in Newly Diagnosed High-Volume mHSPC
38
39
40
41
42
43
44
45
46
47
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free